Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Cells|June 24, 2022
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved TestDamien Vasseur, Hela Sassi, Arnaud Bayle, et al.
Frontiers in Oncology|May 29, 2026
Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scansMatthieu Delaye, Littisha Lawrance, Younes Belkouchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 6, 2026
Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer PatientsSantiago Ponce, Miguel Ruiz-Torres, Alejandro Falcón, et al.
JTO Clinical and Research Reports|April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARDByoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2019
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF TrialMiguel-Angel Molina-Vila, Rolf A Stahel, Urania Dafni, et al.
The Lancet. Oncology|March 31, 2022
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trialHedy L Kindler, Silvia Novello, Alessandra Bearz, et al.
Molecular Cancer|October 4, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX developmentDamien Vasseur, Ludovic Bigot, Kristi Beshiri, et al.
JCO Precision Oncology|March 2, 2023
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid TumorsMihaela Aldea, Marco Tagliamento, Arnaud Bayle, et al.
The Lancet. Oncology|April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialJosé Trigo, Vivek Subbiah, Benjamin Besse, et al.
Science Translational Medicine|October 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumorsIván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz, et al.
Pageof 11